The US Department of Commerce has left unresolved the exact circumstances in which the federal government can require a patent owner or licensee to share its patent rights with another party, but its suggestion that drug pricing is not likely to be a factor for pharma patents will surely drive further debate over the issue before regulations are implemented.
End Of The 'March-In' Pricing Petitions?
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
More from Legal & IP
More from Pink Sheet
• By
The forced departure of CBER Director Peter Marks is a milestone event for the agency, as center directors now are likely to be treated as political positions subject to change with each new administration.
• By
The European Medicines Agency’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam.
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.